Startseite>>Signaling Pathways>> Microbiology & Virology>> HIV>>Bz-RS-iSer(3-Ph)-OMe

Bz-RS-iSer(3-Ph)-OMe

Katalog-Nr.GC39739

Bz-RS-iSer(3-Ph)-OMe (Verbindung 2), ein Taxol-Derivat, hemmt den HSV-Replikationszyklus bei geringer ZytotoxizitÄt, blockiert die mitotische Teilung von Vero-Zellen, beeinflusst die M-MSV-induzierte TumorgrÖße und beeinflusst die Immunantwort durch Hemmung von PHA -induzierte T-Lymphozyten-Proliferation.

Products are for research use only. Not for human use. We do not sell to patients.

Bz-RS-iSer(3-Ph)-OMe Chemische Struktur

Cas No.: 32981-85-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
52,00 $
Auf Lager
100mg
46,00 $
Auf Lager
250mg
93,00 $
Auf Lager
500mg
158,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation[1].

[1]. Krawczyk E, et al. Cytotoxic, antiviral (in-vitro and in-vivo), immunomodulatory activity and influence on mitotic divisions of three taxol derivatives: 10-deacetyl-baccatin III, methyl (N-benzoyl-(2'R,3'S)-3'-phenylisoserinate) and N-benzoyl-(2'R,3'S)-3'-phenylisoserine. J Pharm Pharmacol. 2005;57(6):791‐797.

Bewertungen

Review for Bz-RS-iSer(3-Ph)-OMe

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bz-RS-iSer(3-Ph)-OMe

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.